IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 41 shares, a drop of 96.6% from the August 31st total of 1,214 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 2,201 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IPSEY shares. Zacks Research raised shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

IPSEN Stock Performance

Shares of IPSEY stock opened at $41.97 on Friday. The firm’s 50 day moving average price is $46.15 and its 200-day moving average price is $46.59. IPSEN has a one year low of $32.02 and a one year high of $51.10.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.